

AMPULLA OF VATER STAGING FORM

CLINICAL <i>Extent of disease before any treatment</i>	STAGE CATEGORY DEFINITIONS		PATHOLOGIC <i>Extent of disease during and from surgery</i>																																																																																
☐ y clinical – staging completed after neoadjuvant therapy but before subsequent surgery	TUMOR SIZE: _____		☐ y pathologic – staging completed after neoadjuvant therapy AND subsequent surgery																																																																																
☐ TX ☐ T0 ☐ Tis ☐ T1 ☐ T2 ☐ T3 ☐ T4	PRIMARY TUMOR (T) TX Primary tumor cannot be assessed T0 No evidence of primary tumor Tis Carcinoma <i>in situ</i> T1 Tumor limited to ampulla of Vater or sphincter of Oddi T2 Tumor invades duodenal wall T3 Tumor invades pancreas T4 Tumor invades peripancreatic soft tissues or other adjacent organs or structures other than pancreas		☐ TX ☐ T0 ☐ Tis ☐ T1 ☐ T2 ☐ T3 ☐ T4																																																																																
☐ NX ☐ N0 ☐ N1	REGIONAL LYMPH NODES (N) Regional lymph nodes cannot be assessed No regional lymph node metastasis Regional lymph node metastasis		☐ NX ☐ N0 ☐ N1																																																																																
☐ M0 ☐ M1	DISTANT METASTASIS (M) No distant metastasis (no pathologic M0; use clinical M to complete stage group) Distant metastasis		☐ M1																																																																																
ANATOMIC STAGE • PROGNOSTIC GROUPS																																																																																			
CLINICAL <table border="1"> <thead> <tr> <th>GROUP</th> <th>T</th> <th>N</th> <th>M</th> </tr> </thead> <tbody> <tr><td>☐ 0</td><td>Tis</td><td>N0</td><td>M0</td></tr> <tr><td>☐ IA</td><td>T1</td><td>N0</td><td>M0</td></tr> <tr><td>☐ IB</td><td>T2</td><td>N0</td><td>M0</td></tr> <tr><td>☐ IIA</td><td>T3</td><td>N0</td><td>M0</td></tr> <tr><td>☐ IIB</td><td>T1</td><td>N1</td><td>M0</td></tr> <tr><td></td><td>T2</td><td>N1</td><td>M0</td></tr> <tr><td></td><td>T3</td><td>N1</td><td>M0</td></tr> <tr><td>☐ III</td><td>T4</td><td>Any N</td><td>M0</td></tr> <tr><td>☐ IV</td><td>Any T</td><td>Any N</td><td>M1</td></tr> </tbody> </table> ☐ Stage unknown		GROUP	T	N	M	☐ 0	Tis	N0	M0	☐ IA	T1	N0	M0	☐ IB	T2	N0	M0	☐ IIA	T3	N0	M0	☐ IIB	T1	N1	M0		T2	N1	M0		T3	N1	M0	☐ III	T4	Any N	M0	☐ IV	Any T	Any N	M1	PATHOLOGIC <table border="1"> <thead> <tr> <th>GROUP</th> <th>T</th> <th>N</th> <th>M</th> </tr> </thead> <tbody> <tr><td>☐ 0</td><td>Tis</td><td>N0</td><td>M0</td></tr> <tr><td>☐ IA</td><td>T1</td><td>N0</td><td>M0</td></tr> <tr><td>☐ IB</td><td>T2</td><td>N0</td><td>M0</td></tr> <tr><td>☐ IIA</td><td>T3</td><td>N0</td><td>M0</td></tr> <tr><td>☐ IIB</td><td>T1</td><td>N1</td><td>M0</td></tr> <tr><td></td><td>T2</td><td>N1</td><td>M0</td></tr> <tr><td></td><td>T3</td><td>N1</td><td>M0</td></tr> <tr><td>☐ III</td><td>T4</td><td>Any N</td><td>M0</td></tr> <tr><td>☐ IV</td><td>Any T</td><td>Any N</td><td>M1</td></tr> </tbody> </table> ☐ Stage unknown		GROUP	T	N	M	☐ 0	Tis	N0	M0	☐ IA	T1	N0	M0	☐ IB	T2	N0	M0	☐ IIA	T3	N0	M0	☐ IIB	T1	N1	M0		T2	N1	M0		T3	N1	M0	☐ III	T4	Any N	M0	☐ IV	Any T	Any N	M1
GROUP	T	N	M																																																																																
☐ 0	Tis	N0	M0																																																																																
☐ IA	T1	N0	M0																																																																																
☐ IB	T2	N0	M0																																																																																
☐ IIA	T3	N0	M0																																																																																
☐ IIB	T1	N1	M0																																																																																
	T2	N1	M0																																																																																
	T3	N1	M0																																																																																
☐ III	T4	Any N	M0																																																																																
☐ IV	Any T	Any N	M1																																																																																
GROUP	T	N	M																																																																																
☐ 0	Tis	N0	M0																																																																																
☐ IA	T1	N0	M0																																																																																
☐ IB	T2	N0	M0																																																																																
☐ IIA	T3	N0	M0																																																																																
☐ IIB	T1	N1	M0																																																																																
	T2	N1	M0																																																																																
	T3	N1	M0																																																																																
☐ III	T4	Any N	M0																																																																																
☐ IV	Any T	Any N	M1																																																																																
PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS) REQUIRED FOR STAGING : None CLINICALLY SIGNIFICANT : Preoperative or pre-treatment carcinoembryonic antigen (CEA): _____ Preoperative or pre-treatment CA 19-9 lab value: _____			General Notes: For identification of special cases of TNM or pTNM classifications, the "m" suffix and "y," "r," and "a" prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis. m suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.																																																																																

HOSPITAL NAME/ADDRESS	PATIENT NAME/INFORMATION

(continued on next page)

AMPULLA OF VATER STAGING FORM

Histologic Grade (G) (also known as overall grade)

Grading system

- ☐ 2 grade system
- ☐ 3 grade system
- ☐ 4 grade system
- ☐ No 2, 3, or 4 grade system is available

Grade

- ☐ Grade I or 1
- ☐ Grade II or 2
- ☐ Grade III or 3
- ☐ Grade IV or 4

ADDITIONAL DESCRIPTORS

Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined into Lymph-Vascular Invasion (LVI) for collection by cancer registrars. The College of American Pathologists' (CAP) Checklist should be used as the primary source. Other sources may be used in the absence of a Checklist. Priority is given to positive results.

- ☐ Lymph-Vascular Invasion Not Present (absent)/Not Identified
- ☐ Lymph-Vascular Invasion Present/Identified
- ☐ Not Applicable
- ☐ Unknown/Indeterminate

Residual Tumor (R)

The absence or presence of residual tumor after treatment. In some cases treated with surgery and/or with neoadjuvant therapy there will be residual tumor at the primary site after treatment because of incomplete resection or local and regional disease that extends beyond the limit of ability of resection.

- ☐ RX Presence of residual tumor cannot be assessed
- ☐ R0 No residual tumor
- ☐ R1 Microscopic residual tumor
- ☐ R2 Macroscopic residual tumor

General Notes (continued):

y prefix indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a "y" prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The "y" categorization is not an estimate of tumor prior to multimodality therapy.

r prefix indicates a recurrent tumor when staged after a disease-free interval, and is identified by the "r" prefix: rTNM.

a prefix designates the stage determined at autopsy: aTNM.

surgical margins is data field recorded by registrars describing the surgical margins of the resected primary site specimen as determined only by the pathology report.

neoadjuvant treatment is radiation therapy or systemic therapy (consisting of chemotherapy, hormone therapy, or immunotherapy) administered prior to a definitive surgical procedure. If the surgical procedure is not performed, the administered therapy no longer meets the definition of neoadjuvant therapy.

☐ Clinical stage was used in treatment planning (describe): _____

☐ National guidelines were used in treatment planning ☐ NCCN ☐ Other (describe): _____

Physician signature

Date/Time

HOSPITAL NAME/ADDRESS

PATIENT NAME/INFORMATION

(continued from previous page)